On Jul. 15, 2021, iBio announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (ﾓN proteinﾔ) of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response.

Data on commercially available COVID-19 vaccines – all of which target the spike protein (ﾓS proteinﾔ) – suggested that neutralizing titers are effective, but likely to wane over time.